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Human Mental Retardation (MR) is a common and highly heterogeneous pediatric disorder affecting around 3% of the general
population; at least 215 X-linkedMR (XLMR) conditions have been described, andmutations have been identiﬁed in 83 different genes,
encoding proteins with a variety of function, such as chromatin remodeling, synaptic function, and intracellular trafﬁcking. The small
GTPases of the RAB family, which play an essential role in intracellular vesicular trafﬁcking, have been shown to be involved in MR. We
report here the identiﬁcation of mutations in the small GTPase RAB39B gene in two male patients. One mutation in family X (D-23)
introduced a stop codon seven amino acids after the start codon (c.21C > A; p.Y7X). A second mutation, in the MRX72 family, altered
the 50 splice site (c.215þ1G > A) and normal splicing. Neither instance produced a protein. Mutations segregate with the disease in the
families, and in some family members intellectual disabilities were associated with autism spectrum disorder, epileptic seizures, and
macrocephaly. We show that RAB39B, a novel RAB GTPase of unknown function, is a neuronal-speciﬁc protein that is localized to the
Golgi compartment. Its downregulation leads to an alteration in the number and morphology of neurite growth cones and a signiﬁcant
reduction in presynaptic buttons, suggesting that RAB39B is required for synapse formation and maintenance. Our results demonstrate
developmental and functional neuronal alteration as a consequence of downregulation of RAB39B and emphasize the critical role of
vesicular trafﬁcking in the development of neurons and human intellectual abilities.Introduction
Human Mental Retardation (MR) is a common and highly
heterogeneous pediatric disorder with a severe social
impact. Accounting for a large, but not well-deﬁned,
portion of all MR forms, genetic defects range from 25%–
50% of the total. Family studies have demonstrated a rela-
tively large number of X-linked forms (XLMR) that seem to
explain why the incidence of MR in males is about 30%
higher than in females.1 Because large families are not so
common and many autosomal genes are expected, the
newly identiﬁed genes have served as important tools for
understanding the molecular basis of MR and have
provided novel breakthroughs on the mechanisms and
pathways leading to development of the cognitive func-
tions altered in MR.
As a result, at least 215 XLMR conditions and mutations
have been characterized in 83 different genes. Research on1Dulbecco Telethon Institute at Division of Neuroscience, San Raffaele Scientiﬁ
Raffaele Scientiﬁc Institute, 20132 Milan, Italy; 3Molecular Genetics Laboratory
Universita` di Milano Polo Osp. San Paolo, 20142 Milan, Italy; 5Max Planck In
Genetics, 66424 Homburg (Saar), Germany; 7J.C. Self Research Institute of H
8SA Pathology, Women’s and Children’s Hospital, North Adelaide, SA 5006, A
Australia; 10Center for Human Genetics, University Hospital Leuven, 3000 Leu
de Ge´ne´tique and INSERM, U930, 37044 Tours, France; 12Universite´ Paris Desc
Scientiﬁque, UMR 8104, 75014 Paris, France; 13Department of Human Genet
Brain, Cognition and Behaviour, Radboud University Nijmegen Medical Cen
CNR, 20182 Pavia, Italy
15Present address: Department of Experimental Oncology, European Institute
16Present address: Vascular Biology and Gene Therapy Laboratory, Centro Car
*Correspondence: p.dadamo@hsr.it
DOI 10.1016/j.ajhg.2010.01.011. ª2010 by The American Society of Human
The Americathe role of proteins encoded by these genes led to the
hypothesis that XLMR is a synaptopathy-like disorder
that is due, in part, to the fact that most of these proteins
localize to pre- and/or post-synaptic neuronal terminals.
The identiﬁcation of guanine nucleotide dissociation
inhibitor gene, GDI1 (MIM 300104) as one of the genes
causing human XLMR suggested that vesicular trafﬁcking
is an important pathway for the development of cognitive
functions.2–4 aGDI, the protein encoded by GDI1, is phys-
iologically involved in regulating RAB GTPase proteins.
More than 60 RAB GTPases are encoded by the human
genome and are localized to different subcellular compart-
ments.5,6 Through a GDP-GTP exchange cycle, they act as
molecular switches to coordinate vesicular transport. The
guanine nucleotide-binding status is modulated by three
classes of regulatory proteins, the guanine nucleotide
exchange factors (GEFs), GTPase-activating proteins
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proteins (GDIs), which retrieved GDP-bound, inactive
RAB proteins from the membranes.7 RAB and RAB-associ-
ated proteins have been shown to play an important role
in a number of diseases.8 Thus, the association of GDI1
mutations with XLMR led us to hypothesize a role for
X-linked RAB genes in XLMR. Three out of four X-linked
RAB genes are speciﬁc to the brain, as shown in the
SymAtlas database, and we identiﬁed novel loss-of-func-
tion mutations in the RAB39B (MIM 300774) gene in
two XLMR families. RAB39B is one of the RAB GTPase
proteins of unknown function, and understanding how
the lack of RAB39B is involved in the pathology of XLMR
is therefore particularly relevant for understanding the
pathogenesis of the disease.Material and Methods
Patients and Analysis of the RAB39B Gene
In total, 22 DNA samples frommales with XLMRmapped to Xq28
were obtained from the EuropeanMental Retardation Consortium
in Nijmegen, The Netherlands, from the Greenwood Genetic
Center in North Carolina, USA, and from the MRX72 family
in Italy.9 We also analyzed 136 DNA samples from unmapped
males with XLMR from the Greenwood Genetic Center and the
Women’s and Children’s Hospital, Adelaide, Australia and 110
DNA samples from unmapped males with XLMR from the
European Mental Retardation Consortium in Nijmegen, The
Netherlands. From these samples, 92 were from patients with
XLMR and autism spectrum disorder, 94 from patients with
autism spectrum disorder only, and 94 from Greenwood Genetic
Center patients with epileptic seizures only.
Control DNAs were from a previous collection of adult Euro-
pean males. All patients and controls were recruited and studied
after appropriate ethical approval was obtained. Sequences of
the two exons of RAB39B were obtained by PCR with the primers
R39b1exF/R39b1exR and R39b2exF/R39b2exR. The same primers
were used for direct sequencing on a 3730 automated sequencing
apparatus. Analysis was performed with the SeqScape sequence
analysis software (Applied Biosystems). Sequences were numbered
according to the RAB39B cDNA NM_171998 and protein
NP_741995. Primer sequences are listed in Table S1 available
with this article online.Mutated cDNA Cloning, Transfection,
and Immunoblotting
Total RNA from a normal subject, family X (D-23), and MRX72
male patients was extracted from lymphoblastoid cell lines
with the RNeasy kit (QIAGEN). RNA was reverse transcribed
with M-MLV enzyme (Invitrogen). cDNAs were ampliﬁed with
primers R39b1exF/R39b2exR, inserted into pGEM-T easy vector
(Promega), and ampliﬁed with speciﬁc primers HindhR39bF/
BamhR39bR so that they could be cloned in frame into HindIII
and BamHI sites of pCMV2-FLAG plasmid (Sigma-Aldrich).
pFLAG-RAB39B constructs were transfected into HeLa cells with
Lipofectamine 2000 (Invitrogen), as recommended by the sup-
plier. Two days after transfection, cells were harvested and lysed
in 1% SDS. Total protein extracts (30 mg) were loaded onto a
10% polyacrilamide gel and then transferred on a nitrocellulose
membrane. Polyclonal anti-FLAG antibody (Sigma-Aldrich) was186 The American Journal of Human Genetics 86, 185–195, Februaryused for detecting the presence of the protein, and beta-Tubulin
was used for normalizing the total amount of protein. Primer
sequences are listed in Table S1.
RAB39B Expression Proﬁle in Human and Mouse
Tissues by qRT-PCR
Human RNA from various tissues was purchased from Clontech.
Mouse tissue RNAs were obtained from different C57BL/6N adult
mouse organs (Charles River). Total RNA was isolated with TRIzol
reagent (Invitrogen) according to the manufacturer’s instructions.
For the production of cDNA, 1 mg of total RNA was reverse
transcribed with M-MLV enzyme (Invitrogen) according to the
manufacturer’s instructions.
Real-time PCR was performed with SYBR Green Universal Mix
(Sigma-Aldrich) on a Light Cycler 480 (Roche Diagnostics).
Samples were run in triplicate, and data quantiﬁcation was done
via the comparative threshold cycle (Ct) method with formula
2-(inputCt-controlCt), assuming that the efﬁciency was 2. Histone H3
with mHistone3F/mHistone3R primers was used for normaliza-
tion.HumanRAB39B and themouseRab39b cDNAswere ampliﬁed
with the same primer pairs, mR39bF/mR39bR. Mouse Rab39a was
ampliﬁed with primers R39aF/R39aR. Primer sequences are listed
in Table S1.
In Situ Hybridization
In situ hybridization was performed on P90 mouse brains with
anti-sense and sense RNA probes containing part of the 30UTR of
Rab39b, as previously described.3
Cell Cultures
Primary cultures of hippocampal neurons at embryonic day E18
were prepared as described by Banker and Cowan.10 Cells were
grown in MEM supplemented with 10% FBS, 1% glutamine, and
1% penicillin and streptomycin.
cDNA Constructs and MISSION shRNAValidation
For transfection experiments, different plasmid backbones were
generated.
For production of pEGFP-RAB39B, the PCR product obtained
from mouse Rab39b cDNA clone (BC052472) was cloned with
primers R39bgfpF/R39bgfpR into XhoI and HindIII sites of
pEGFP-C3 (Clontech).
For production of pEGFP-RAB39A, the PCR product obtained
from C57Bl/6N total brain cDNA was cloned with primers
R39AF/R39AR into XhoI and HindIII sites of pEGFP-C3.
For production of pFLAG-RAB39B, the PCR product obtained
from the BC052472 clone was cloned with primers R39bﬂagF/
R39bﬂagR into NotI and KpnI sites of pCMV2-FLAG (Sigma-
Aldrich).
For generationof pFLAG-RAB39BRescue, theRab39b sequence of
pFLAG-RAB39B was modiﬁed with the QuickChange Site-Directed
Mutagenesis Kit (Stratagene) and primer pairs RescueR39bF/Rescu-
eR39bR. The sequence GCCTACTACAGGAATTCAGTA was re-
placed with the sequence GCGTATTACCGGAACTCCGTC, which
did not change the amino acid composition of RAB39B but
rendered the construct insensitive to the Rab39b-speciﬁc shRNA.
VSV-pseudotyped third-generation lentiviruses were produced
as previously described.11 Rab39b was excised via AgeI and SalI
sites from pEGFP-RAB39B and cloned into the AgeI and SalI
sites of pCCL.sin.cPPT.PGK.GFP.WPRE plasmid (pCCL-RAB39B)
carrying a PGK promoter-GFP cassette.1112, 2010
For the Rab39b silencing experiments, four MISSION shRNAs
recognizing different sequences on the Rab39b cDNA (code
TRC000046, 47, 48, and 49) and control scramble shRNA were
purchased from Sigma-Aldrich. HeLa cells transfected with
pEGFP-RAB39B or pEGFP-RAB39A and transduced with the
different shRNAs at a multiplicity of infection (MOI) of 1 or 3
were analyzed by both immunoblot and qRT-PCR so that the
capacity of shRNAs to speciﬁcally knock down Rab39b expression
could be tested. Three out of four shRNAs were able to downregu-
late Rab39b, but not Rab39a, by about 60%. Control-scramble
shRNA (shScramble), TRC000047, and 49 shRNAs (shRab39b)
were introduced into pCCL.sin.cPPT.PGK.GFP.WPRE lentiviral
vector.
Primer sequences are listed in Table S1.
Cell Transfection and Transduction
For the intracellular localization of RAB39B by immunoﬂuores-
cence experiments, N2A, HeLa, and Cos7 cells were transfected
with Lipofectamine 2000 (Invitrogen) according to the manufac-
turer’s instructions. So that overexpression of RAB39B did not
occur, different amounts of plasmids encoding pEGFP-RAB39B
were tested. The convenient condition was 350 ng for N2A and
100 ng for HeLa and Cos7 cells instead of 4 mg as suggested by
the supplier.
So that overexpression of RAB39B in hippocampal neurons did
not occur, cells were transduced with pCCL-RAB39B lentivirus at
an MOI of 1 immediately after plating.
For the rescue experiment, N2A cells were transduced with
shRab39b or shScramble lentiviral particles at an MOI of 3, and
after 4 days they were transfected for 24 hr with 130 ng of
pFLAG-RAB39BRescue or pFLAG-RAB39B. The Rab39b level was
analyzed by qRT-PCR as previously described.
BFA Treatment
Two days after transfection with pEGFP-RAB39B, N2A, HeLa or
Cos7 cells were treated with 2.5 mg/ml of Brefeldin A (Sigma-
Aldrich) for 30 min at 37C.
FM4-64 Uptake Assay
For FM4-64-uptake experiments, neurons were incubated with
10 mM FM4-64 (Molecular Probes) diluted in Krebs-Ringer-HEPES
solution (KRH) containing 55 mM KCl (depolarizing solution)
and 1 mM TTX for 1 min at room temperature (RT), rinsed three
times by complete substitution with KRH containing 50 mM
CNQXand1mMTTXover a courseof10min,andthen live imaged.
Immunoﬂuorescence and Microscopy
Cells were ﬁxed with 120 mM phosphate buffer containing 4%
paraformaldehyde and 4% sucrose, washed in PBS 1x, and then
incubated overnight at 4C with primary antibodies diluted in
GSDB 1x (16%Goat Serum, 0.3% Triton X-100, 20 mM phosphate
buffer, and 450 mM NaCl). Primary antibodies against the
following proteins were used for immunoﬂuorescence: GM130
(BD Transduction), GIANTIN (gift from M.A. De Matteis),
RAB3A, VAMP4, STX16, STX13 (SySy), RAB11 (Transduction Labo-
ratories), Flag (Sigma), AP2 (Afﬁnity BioReagents, clone AP6),
SYN1 (gift from F. Valtorta), and SHANK1 (gift from C. Sala). After
cells were washed in a high-salt solution (20mM phosphate buffer
and 500 mM NaCl), appropriate rhodamine (TRITC)- or Cy5-
conjugated secondary antibodies (Jackson Laboratories) were
added for 1 hr at RT. DAPI was used for visualizing cell nuclei.The AmericaTRITC-conjugated phalloidin (Sigma-Aldrich) was used for visual-
izing F-Actin. Slides were mounted on Vectashield (VectaLab).
Images were acquired by UltraVIEW ERS spinning-disk confocal
microscope (Perkin Elmer).
Image Analysis
ImageJ Analysis Software was used for measuring the area of
neuronal growth cones. Sholl analysis was performed as previ-
ously described12 so that the degree of neuronal differentiation
could be analyzed.
Statistical Analysis
Factorial or repeated-measures analysis of variance (ANOVA) with
an alpha value of 5% was used (SAS Institute, Cary, NC). Normal
distribution and homogeneity of variances among data samples
was tested with the K-S normality test and Bartlett’s test for
homogeneity. Main effects were veriﬁed with t tests. Data points
represent the mean, and bars represent the standard error.
Animals
All experiments with animals were performed in strict accordance
with the guidelines of the Institutional Animal Care and Use
Committee of the Department of Biological and Technological
Research, San Raffaele Scientiﬁc Institute.Results
Detection of Mutations in the RAB39B Gene
We examined 22 XLMR families that mapped to Xq28 to
determine whether RAB39B was responsible for XLMR.
From the genomic sequence of RAB39B, primers were de-
signed for direct sequencing of the two exons and the
ﬂanking splice sites of this gene. A nonsense mutation
(NM_171998, c.21C > A) in family X (D-23) introduced
a premature stop codon seven amino acids after the start
codon (TAA; NP_741995, p.Y7X; Figure 1A). In the
MRX72 family, a nucleotide substitution (NM_171998,
c.215þ1G > A) altered the 50 splice junction of intron 1
(Figure 1B). Using RT-PCR, we demonstrated that a cryptic
50 splice donor site (GT at 46–47 bp of cDNA, NM_171998)
was activated in the ﬁrst exon and produced an aberrant
mRNA that could lead to synthesis of a putative novel
peptide of 52 amino acids in length (data not shown). In
both cases, immunoblotting of HeLa cells transfected
with FLAG-tagged mutated and control cDNAs did not
detect any mutant protein (Figure 1C). The mutations
segregated with the disease in both families as shown in
the family pedigrees (Figures 1D and 1E). Sequencing of
150 normal chromosomes demonstrated that the muta-
tions were not common polymorphisms.
Patients in both families presented with moderate to
severe MR, as well as additional features; in the MRX72
family, III-9, III4, and III-5 had seizures, and IV-5 presented
with autism spectrum disorder (Figure 1E).9 In family X
(D-23), four brothers (III-1, III-2, III-3, and III-4) and two
maternal uncles (II-3 and II-4) were mentally retarded,
and these six patients presented with macrocephaly, as
described in Table 1.n Journal of Human Genetics 86, 185–195, February 12, 2010 187
Figure 1. RAB39B Mutations in Family X (D-23) and MRX72
(A and B) The upper panels show the corresponding sequence
from a normal individual; the lower panels are from the patients.
Arrows indicate the mutations. Sequence numbers refer to the
human RAB39B cDNA (NM_171998).
(C) Immunoblot analysis performed on 30 mg of total protein
extracted from HeLa cells transfected with pFLAG-RAB39B con-
structs containing the wild-type RAB39B cDNA (WT), family X
(D-23) mutated cDNA, or MRX72 cDNA. The 24-kDa band corre-
sponds to FLAG-RAB39B fusion protein, and the 51-kDa band
corresponds to beta-tubulin. MOCK: cells transfected with
pCMV2-FLAG. NT: cells not transfected.
(D) Pedigree of family X (D-23).
(E) Pedigree of MRX72. Black squares indicate males with mental
retardation, dotted circles indicate carrier females, and open
symbols indicate unaffected individuals. Asterisks indicate family
members who have been sequenced in this study.Because of the presence of seizures and autism spectrum
disorder in family X (D-23) and MRX72, we analyzed 526
DNA samples from unmapped X-linked patients with188 The American Journal of Human Genetics 86, 185–195, Februaryseizures and autism spectrum disorder. We found the
same synonymous variation (c.822A > G, p.T181T) that
Tarpey et al.13 described previously in two unrelated
autistic males.
RAB39B Is Highly Enriched in the Brain
We performed qRT-PCR on several human and mouse
tissues to analyze RAB39B expression. We demonstrated
that RAB39B is enriched in the brain (Figures 2A and 2B).
During postnatal (P) mouse brain development, Rab39b
expression is constant between P1 and P10, as well as
between P20 and P180. A signiﬁcant difference was
observed between P10 to P20, where Rab39b was upregu-
lated 2-fold as calculated by the t test (p ¼ 0.003). We
also analyzed the expression proﬁle of the Rab39a gene,
which has 72% and 76% identity at the cDNA and protein
levels, respectively. The Rab39a transcript was expressed at
levels ten times less than Rab39b and does not increase at
all stages analyzed. These results demonstrated that
Rab39b is a brain-speciﬁc gene with an important role (Fig-
ure 2C). Expression analysis of the Gdi1 null brains re-
vealed no change, suggesting that absence of aGDI did
not alter Rab39b RNA levels, as previously shown for other
RAB proteins3 (data not shown).
Rab39b Is a Neuron-Speciﬁc Gene
Rab39b appeared to be ubiquitously expressed in brain, as
determined by in situ hybridization on sagittal sections
of adult (P90) mouse brain. The highest expression
was observed in the hippocampus, as shown in Figures
3A–3F.
We further analyzed the Rab39b neuronal cellular speci-
ﬁcity. We dissected and dissociated P2 mouse cerebral
cortices to obtain different neuronal cell types such as
microglia, oligodendrocytes, astrocytes, neuronal precur-
sors, and neurons, as described.14 By qRT-PCR, we quanti-
ﬁed the Rab39b expression in these cell types and showed
that Rab39b was speciﬁcally expressed in neuronal precur-
sors and neurons only (Figure 3G).
RAB39B Localizes to the Golgi Compartment
We analyzed the intracellular localization of RAB39B in
pEGFP-RAB39B-transfected Cos7 and HeLa cells (data not
shown), and in a pCCL-RAB39B-transduced neuroblas-
toma cell line, N2A (Figure S1a), and primary hippocampal
neurons (Figure 4). In all instances, RAB39B appeared
to localize to the Golgi compartment, as judged from the
colocalization with the Golgi markers, GIANTIN and
GM130. We conﬁrmed the Golgi localization by treating
N2A cells for 30 min with or without brefeldin A (þ BFA
and  BFA), respectively (Figure S1b). GFP-RAB39B and
anti-GIANTIN immunostaining, as well as GFP-RAB39B
immunostaining after BFA treatment, showed dispersion
of the Golgi compartment. We also observed a partial
colocalization with markers that cycle from the cell sur-
face to the trans-Golgi network (TGN) via sorting and
recycling endosomes such as VAMP4, SYNTAXIN16, and12, 2010
Table 1. Clinical Evaluation of Family X (D-23)
Clinical Feature II-3 II-4 III-1 III-2 III-3 III-4
Age (yr) 52 50 19 16 13 13
Height (cm) 163
(<3rd percentile)
170
(3rd percentile)
178.5
(50th percentile)
177.5
(50th percentile)
145.5
(3rd percentile)
145.7
(3rd percentile)
OFC 59
(>97th percentile)
62.5
(>97th percentile)
60.5
(>97th percentile)
56.5
(>97th percentile)
57
(>97th percentile)
56.5
(>97th percentile)
Degree of MR mild severe moderate moderate moderate severe
Additional features - - obesity - autism autism
In family X (D-23), four brothers and two maternal uncles were mentally retarded. The pedigree of the family is shown in Figure 1D. Patients III-3 and III-4 were
twins. A sister of the two uncles (II-7) was mentally normal and died of a brain tumor at the age of 21 years. The degree of mental retardation ranged from mild
(II-3) to severe (II-4 and III-4). All six patients had macrocephaly. Brain MRI scans in patients III-3 and III-4 and a CT scan in patient III-1 revealed no abnormalities.
Height ranged from short stature in II-3, II-4, III-3, and III-4 to normal height in III-1 and III-2. Clinical examination of the patients revealed neither additional
malformations nor significant facial dysmorphic features.RAB11.15–17 The latter subcellular colocalization suggests
a possible role of RAB39B in the recycling pathway con-
necting the plasma membrane, endosomes, and TGN.
Downregulation of Rab39b by shRNA
Undifferentiated N2A cells were infected with two inde-
pendent shRNAs against Rab39b at an MOI of 3. As deter-
mined by qRT-PCR after 5 days of infection, both shRNAs
were able to downregulate the endogenous Rab39b expres-
sion by 45%, expressed as n-fold changes (5 standard error
[SE]) relative to untreated cells (shRab39b: 0.555 0.02). In
contrast, shScramble did not have any effect (shScramble:
0,91 5 0.006) (Figure S2a).
The speciﬁcity of shRab39b was determined by a knock-
down-rescue experiment. N2A cells were transduced with
the shRab39b lentiviral particles for 4 days and then trans-
fected with the full-length wild-type Rab39b (pFLAG-
RAB39B) or pFLAG-RAB39BRescue constructs. In cells
treated with shRab39b and transfected with pFLAG-
RAB39B, the wild-type pFLAG-RAB39B expression was
downregulated by 45% in comparison to pFLAG-
RAB39B-transfected cells as determined by qRT-PCR
(shRab39b þ pFLAG-RAB39B: 0.555 0.1; value expressed
as n-fold changes 5 SE). We also showed that shRab39b
was not able to downregulate the rescue Rab39b transcript
(Figures S2b and S2c).
After 4 days of treatment with the shRab39b lentivirus,
we observed a change in N2A cell morphology. To further
investigate the morphological phenotype, we stained N2A
shRab39b lentivirus-treated cells with phalloidin as a
marker for actin cytoskeleton morphology. We found
clumps of actin and reduced and/or altered membrane
protrusions that were not present in shScramble-treated
N2A cells (Figure S2d). After 4 days, transfection of
shRab39b-treated N2A cells with pFLAG-RAB39BRescue
for 24 hr was able to restore the normal actin cytoskeleton
morphology.
These results suggested that the downregulation of
Rab39b might alter intracellular vesicular trafﬁcking steps
important for membrane remodeling.The AmericaDownregulation of Rab39b Gene Alters Neuronal
Differentiation
To mimic the loss-of-function mutations identiﬁed in
patients, we knocked down Rab39b expression in mouse
primary hippocampal neurons. Immediately after plating,
hippocampal neurons were transduced with shRab39b and
shScramble lentiviral particles at an MOI of 1. ShRAB39b
was able to reduce Rab39b expression by 40%, as deter-
mined at 3 days in vitro (DIV) by qRT-PCR. Morphological
analysis from 80 shScramble and 124 shRab39b randomly
sampled images from four independent experiments
showed a signiﬁcant alteration in morphology and the
number of growth cones (GCs; Figure 5A). GCs were
decreased in number at each neurite terminal. The mean
number of GCs per neurite (5SE) was 3.1 (50.1) for
shRAB39b and 3.8 (50.1) for shScramble neurons. The
difference was signiﬁcant (ANOVA: F [1,202] ¼ 8.2;
p ¼ 0.005). The mean area of GCs (5SE) was 38.7 (52.8)
for shRab39b and 30.8 (52.4) for shScramble neurons.
The difference was signiﬁcant (ANOVA: F [1,202] ¼ 3.8,
p ¼ 0.05) (Figures 5B and 5C; see the enlargement in the
right panel).
Sholl analysis,12 as ameasure of neuronal differentiation,
was performed on 62 shScramble and 87 shRab39b
randomly sampled images from three independent experi-
ments and also revealed a signiﬁcant decrease in the
number of neuronal branches: repeated-measures ANOVA
between treatments had a value of F [1,147] ¼ 6.6,
p ¼ 0.01 and showed an interaction between treatment
and Sholl category (mm from the cell body): F [1,5] ¼ 2.3,
p¼ 0.04. Factorial ANOVA for each Sholl category revealed
signiﬁcant p values for 30 mm (F [1,147] ¼ 9.3, p ¼ 0.003),
35 mm (F [1,147] ¼ 7.6, p ¼ 0.006), and 40 mm (F [1,147] ¼
7.2; p ¼ 0.007) (Figure 5D). Taken together, these data
suggest a global alteration in neurite extension.
RAB39B Was Localized to GCs
To test whether RAB39Bwas present in GCs, we transduced
primary hippocampal neurons at 3 DIV with pCCL-
RAB39B lentiviral particles. We found that GFP-RAB39Bn Journal of Human Genetics 86, 185–195, February 12, 2010 189
Figure 3. Rab39b Is Specifically Expressed in Neurons
(A) In situ hybridization analysis of Rab39b on P90 mouse brain.
Light-microscopic images showing the distribution of Rab39b
mRNA in 20 mm mouse brain sagittal sections. Anti-sense (A)
and sense (B) Rab39b probe.
(C–F) Enlargements of speciﬁc regions: CC, cerebral cortex; CbC,
cerebellar cortex; Hi, hippocampus; OB, olfactory bulb; T, thal-
amus; S, subiculum; CA1 and CA3, ﬁelds of the hippocampus;
DG, dentate gyrus; PL, Purkinje layer; and Mi, mitral cells. Scale
bars represent 2 mm (A and B) and 0.1 mm (C–F).
(G) Rab39b expression normalized to Histone-H3 (2-DCt(Rab39b–H3))
in neuronal cell types. P2 mouse cerebral cortices were dissected,
dissociated in trypsin medium, and plated. Different neuronal
cell types were prepared as described.14 Rab39b is speciﬁcally
expressed in neuronal precursors and neurons.
Figure 2. Expression Analysis on Different Human and Mouse
Tissues
(A) Expression of RAB39B transcript in different human tissues.
(B) Expression of Rab39b transcript in mouse tissues.
(C) Expression proﬁle of Rab39b and Rab39a in mouse total brain
during post-natal (P) development (from P1 to P180; for each age
point, n¼ 8). Data were expressed as Rab39b or Rab39a expression
normalized to Histone-H3 (2-DCt(Rab39b–H3)) (5SE).signals were spread in the whole GC area, as shown by
phalloidin staining (Figure 6A), and some discrete signals
colocalized with the Golgi-derived vesicles, as shown in
the double labeling with GIANTIN (Figure 6B). All these
data suggested that RAB39B could be involved in intracel-
lular trafﬁcking related to membrane recycling of Golgi-
derived vesicles; its reduction may impede such trafﬁcking
and thus lead to an accumulation in the membrane
content and disorganized growth of GCs.
RAB39B Is Involved in Synapse Formation
Next, we looked at the subsequent formation of pre-
synaptic terminals of primary neurons transduced
immediately after plating with shRab39b and shScramble
lentiviral particles at an MOI of 1 until 7 DIV. The downre-190 The American Journal of Human Genetics 86, 185–195, Februarygulation of endogenous Rab39b RNA levels was quantiﬁed
at 7 DIV by qRT-PCR, and we found that the Rab39b
expression was 70% reduced in shRab39b-treated neurons
compared with shScramble-treated neurons.
Analysis of SYNAPSIN1-positive puncta, a marker of
the presynaptic compartment, revealed 49% reduction in
the mean number of synapses. The quantiﬁcation of the
mean number of synapses (5SE) obtained from 56
shRab39b-treated neurons was 115 (59.2), compared
with 223 (517.7) from 53 shScramble randomly sampled
images from three independent experiments. Factorial12, 2010
Figure 4. RAB39B Intracellular Localization in Mouse Hippo-
campal Neurons
Neurons were transduced at 3 DIV with pCCL-RAB39B lentiviral
particles (green) at an MOI of 1 and analyzed at 7 DIV. The
major colocalization was with GM130 (cis-Golgi) and GIANTIN
(Golgi complex), VAMP4 and SYNTAXIN16 (STX16)—involved
in trafﬁcking from the cell surface to the trans-Golgi network
(TGN)—and SYNTAXIN13 (STX13) and RAB11, which are present
in recycling endosomes. No colocalization was observed with the
adaptor protein 2 (AP2). The scale bar represents 10 mm.
The AmericaANOVA revealed F [1,97]¼ 32.7 and p< 0.0001 (Figures 7A
and 7B). We then measured FM4-64 uptake to analyze the
ability of the synaptic vesicles in the remaining synapses to
engage in exo- and endocytosis. The quantiﬁcation of 85
shRab39b and 93 shScramble randomly sampled images
from three independent experiments revealed that the
recycling of synaptic vesicles appeared to be unaffected
because no gross differences in exo- or endocytosis activity
were observed. Instead, FM4-64-positive labeling (5SE)
showed a 40% reduction in shRab39b neurons (163 5
8.9) compared to shScramble-treated (272 5 12) ones,
and a signiﬁcant difference was observed by factorial
ANOVA (F [1,151] ¼ 50.7, p < 0.0001) (Figure 7C). These
data suggest that the alteration observed in neurite exten-
sion at 3 DIV might lead to defective synapse formation or
instability.Discussion
The four X-linked RAB genes were considered as candidate
genes for XLMR. Mutation analysis was started on the
RAB39B gene, and here we have demonstrated that
when mutated, the gene can cause XLMR. We report the
identiﬁcation of two independent point mutations in
two unrelated families affected with XLMR. These muta-
tions disrupt the synthesis of RAB39B by introducing a
premature stop codon in the open reading frame. The
mutations cosegregated with the disease and were not
found in 150 controls. Some of the affected males from
both families primarily presented with mental retardation
associated with autism spectrum disorder, epileptic
seizures, and macrocephaly. This adds further evidence
that XLMR is a highly heterogeneous condition in which
the genetic background and/or environmental factors
contribute to determining the clinical phenotype.
More than 60 RAB GTPases are encoded by the human
genome and localize to different subcellular compart-
ments.6 Through a GDP-GTP exchange cycle, they act as
molecular switches to coordinate vesicular transport. The
association of these proteins and their regulators with
many diseases reﬂects the physiological importance of
RAB GTPases, which is not surprising in light of their
central role in membrane trafﬁcking. To date, mutations
in two RAB GTPases have been found in association with
hereditary neurological disorders. RAB7 (MIM 602298)
mutations are responsible for Charcot-Marie-Tooth type
2B neuropathy (CMT2B [MIM 600882])18 and ulcero-muti-
lating neuropathy,19 and Rab23 (MIM 606144) mutations
are responsible for Carpenter syndrome (ACPSII [MIM
201000]) characterized by cranial-suture defects.20 Among
X-linked genes and in addition to GDI1 (MIM 300104),
mutation analysis in the three X-linked RAB genes could
be helpful to highlight new XLMR genes and further
evaluate the prevalence of mutations in this gene family
in MR. Along the same lines, we should also mention
the ﬁnding of mutations in the Rab3 p130 GAP genen Journal of Human Genetics 86, 185–195, February 12, 2010 191
Figure 5. RAB39B Is Involved in Neurite Differentiation
Hippocampal neurons were transduced with lentiviral particles
containing shRab39b and shScramble at an MOI of 1. The down-
regulation of the endogenous Rab39b RNA level was quantiﬁed at
3 DIV by qRT-PCR, and 40% reduction was observed in shRab39b-
transduced neurons.
(A) There was a signiﬁcant difference (p ¼ 0.005) in the mean
number of growth cones (GCs) at each neurite terminal (5SE)
in shRab39b neurons (3.1 5 0.1) versus shScramble neurons
(3.8 5 0.1) (mean5 SEM).
(B) There was a signiﬁcant difference (p ¼ 0.05) in the mean area
of GCs (5SE) in shRab39b neurons versus shScramble neurons
(38.75 2.8 [mean5 SEM] and 30.8 5 2.4, respectively).
(C) TRITC-Phalloidin immunostaining revealed altered GC
morphology (enlargement of GC morphology in right panel).
The scale bar represents 10 mm.
(D) For Sholl analysis,12 as a measure of neuronal differentiation,
a mask of concentric circles 5 mm apart was created and superim-
posed on neuronal cells. The ﬁrst 10 mm from the center of the
mask corresponds to the neuronal cell body. Repeated-measures
ANOVA revealed signiﬁcant differences between treatments,
where F (1,147) ¼ 6.6, p ¼ 0.01, and between treatment and Sholl
category (mm from the cell body), where F (1,5) ¼ 2.3, p ¼ 0.04.
Factorial ANOVA for each Sholl category revealed a signiﬁcant p
192 The American Journal of Human Genetics 86, 185–195, February(MIM 602536) in Warburg Micro Syndrome (WARBM
[MIM 600118])21 and Martsolf Syndrome (MIM
212720),22 severe autosomal-recessive disorders character-
ized by developmental defects and mental retardation that
are possibly also due to an alteration in neuronal intracel-
lular trafﬁcking.
The exact cellular localization, tissue expression proﬁle,
and physiological function of many RAB GTPases is still
unknown, and this is the case for RAB39B. We showed
that Rab39b is a brain-enriched gene that is speciﬁcally
expressed in neurons. A polyclonal antibody against the
C terminus hypervariable amino acid sequence of
RAB39B was produced but failed to work in immunoﬂuo-
rescence experiments. We investigated the cellular
localization by using a GFP-RAB39B fusion protein, and
we tried to minimize the overexpression by using lentiviral
infection at an MOI of 1 and at least three different cell
types. We observed a diffuse staining in the cytoplasm
and in the nucleus in our experiments; this staining was
possibly caused by GFP-RAB-fused proteins, as shown by
several papers reporting a similar diffuse pattern after
transfection of RAB proteins to determine intracellular
localization.23,24 We cannot demonstrate that this is the
case, but we think this is an unspeciﬁc staining possibly
due to GFP tagging.
We showed that GFP-RAB39B fusion protein partially
colocalized with known proteins of the Golgi compart-
ment and with markers that cycle from the cell surface to
the trans-Golgi network (TGN) via sorting and recycling
endosomes. The latter subcellular colocalization suggests
a possible role for RAB39B in the recycling pathway con-
necting the plasma membrane, endosomes, and TGN.
Searching for interacting RAB39B proteins led to the iden-
tiﬁcation of different proteins, including one Golgi-associ-
ated protein (unpublished data). These preliminary data
further support the localization of RAB39B to the Golgi
compartment.
We investigated the effect of loss-of-function mutations
identiﬁed in XLMR patients. We used the RNA interference
technology (shRNA) to knock down the Rab39b gene in
mouse primary hippocampal neurons and investigate a
possible effect on neuronal development and connectivity.
To test a possible off-target silencing effect25 and downre-
gulation speciﬁcity, we used three shRNAs targeting
different portions of the Rab39b cDNA in N2A cells and
performed a knockdown-rescue experiment. Our data
showed that all shRNAs were able to downregulate the
expression of Rab39b but not Rab39a, which shares high
sequence homology with Rab39b. N2A shRNA-treated cells
revealed clumps of actin and altered membrane protru-
sions that returned to normal in the knockdown-rescue
experiment, as a model of membrane remodeling.value for 30 mm [F (1,147) ¼ 9.3, p ¼ 0.003], 35 mm [F (1,147) ¼
7.6, p ¼ 0.006], and 40 mm [F (1,147) ¼ 7.2; p ¼ 0.007].
*p < 0.05; **p < 0.01; ***p < 0.001. Data are expressed as
means5SE.
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Figure 6. RAB39B Localizes to Golgi-
Derived Vesicles
(A) Hippocampal neurons transduced
immediately after being plated with
pCCL-RAB39B lentiviral particles at an
MOI of 1 and immunostained at 3 DIV.
TRITC-Phalloidin and anti-Tuj1 immunos-
taining revealed that RAB39B occupied
a region similar to that of the GC actin
domain.
(B) A partial colocalization was observed
with GIANTIN, as a marker for the Golgi-
derived vesicles, as shown by the arrows
in the enlargement in the merged right
panel.
The scale bar represents 10 mm.In primary hippocampal neurons, Rab39b downregula-
tion resulted in the alteration of growth cone morphology
and neuronal branching and a global alteration in neurite
arborization. Localization of RAB39B to the growth cones,
and the essential role of Golgi-derived vesicles for the
successful generation of a functional GC,26 suggest that
RAB39B could be involved in intracellular trafﬁcking
related to membrane recycling throughout Golgi-derived
vesicles. The reduction of RAB39B might impede such traf-The American Journal of Human Genﬁcking and lead to an accumulation
in the membrane and disorganized
growth of GCs. The observed alter-
ation in neurite extension might be
the cause of defective synapse forma-tion or instability, as shown in adult hippocampal
neurons. Rab39b downregulation resulted in a drastic
reduction in the total number of synapses without gross
differences in synaptic-vesicle recycling in the remaining
synapses.
In conclusion, we identiﬁed mutations in the neuron-
speciﬁc RAB39B gene, a new gene for XLMR associated
with autism spectrum disorder, epileptic seizures, and
macrocephaly.Figure 7. RAB39B Is Involved in Synapse
Formation
Hippocampal neurons were transduced
immediately after being plating with
shRab39b and shScramble lentiviral parti-
cles at an MOI of 1. The downregulation
of the endogenous Rab39b RNA level was
quantiﬁed at 7 DIV by qRT-PCR, and 70%
reduction was observed in shRab39b-
transduced neurons. (A and B) SYNAPSIN1
immunostaining and quantiﬁcation
showed a 49% reduction in the SYN1 pre-
synaptic compartment on shRab39b
compared to shScramble neurons.
(C) FM4-64-positive labeling showed a
40% reduction for shRab39b neurons
compared to shScramble.
The scale bar represents 10 mm. ***p <
0.001. Data are expressed as means5SE.
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We showed that RAB39B seems to play a key role in
synapse formation, possibly by mediating an intracellular
pathway connecting the plasma membrane, endosomes,
and TGN and possibly in the organization of neuronal
circuits. Further experiments are needed to elucidate the
biological function of RAB39B and the alterations in
neuronal organization and connectivity caused by its
absence.Supplemental Data
Supplemental Data include two ﬁgures and one table and can be
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